Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

KMZ reported for 9 months of 2023 by RAS

10/10/23 KMEZ

RusHydro remains interested in the Krapivinskaya HPP project

10/10/23 HYDR

PepsiCo reported for 9 months of 2023

10/10/23 PEP

Raspadskaya reported for 9 months of 2023 by RAS

10/10/23 RASP

Yandex.Business entered the market of Kazakhstan

10/10/23 YNDX

Sberbank reported for 9 months of 2023 by RAS

10/10/23 SBER

PIK's new shareholder does not intend to interfere in the developer's strategy

10/10/23 PIKK

Fix Price plans to redomicile from Cyprus to Kazakhstan

10/9/23 FIXP

Owners of 43% of Phosagro shares filed claims against Euroclear for ₽3.4 billion

10/9/23 PHOR

Veon closed the sale of Russia's Vimpelcom to management

10/9/23 VEON